

Supplementary Table 1. Postprandial changes in lipid profile, glucose metabolism, and endothelial function in the alogliptin and control groups over time.

Variable	Fasting	2 h	4 h	6 h	8 h
Biochemical parameters					
<u>Total-C (mg/dl)</u>					
Control	185 ± 11	185 ± 10	185 ± 10	188 ± 10	189 ± 11
Alogliptin	181 ± 10	181 ± 10	178 ± 10	184 ± 10	186 ± 10
<u>LDL-C (mg/dl)</u>					
Control	103 ± 9	100 ± 9	101 ± 9	104 ± 9	105 ± 10
Alogliptin	102 ± 9	101 ± 9	99 ± 9	103 ± 9	105 ± 9
<u>TG (mg/dl)</u>					
Control	74 ± 10	120 ± 11	116 ± 14	87 ± 10	61 ± 6
Alogliptin	63 ± 8	99 ± 11*	84 ± 13*	82 ± 13	62 ± 8
<u>RLP-C (mg/dl)</u>					
Control	8.4 ± 1.2	12.1 ± 1.2	12.4 ± 1.2	10.7 ± 0.9	8.3 ± 0.7
Alogliptin	6.7 ± 0.8	10.3 ± 1.1*	9.5 ± 1.4*	9.1 ± 1.4	7.2 ± 0.9
<u>ApoB-48 (µg/ml)</u>					
Control	2.5 ± 0.3	5.1 ± 0.5	4.2 ± 0.5	2.8 ± 0.4	1.9 ± 0.2
Alogliptin	2.2 ± 0.2	4.3 ± 0.4*	3.4 ± 0.4	2.5 ± 0.3	1.6 ± 0.2
<u>Glucose (mg/dl)</u>					
Control	93 ± 2	102 ± 4	91 ± 4	92 ± 2	91 ± 2
Alogliptin	94 ± 2	97 ± 6	90 ± 3	92 ± 2	90 ± 2

Glucagon (pg/ml)

Control	64 ± 5	71 ± 7	59 ± 5	66 ± 5	62 ± 6
Alogliptin	60 ± 3	58 ± 4	55 ± 3	54 ± 3*	58 ± 3

GLP-1 (pmol/l)

Control	3.2 ± 0.2	8.4 ± 1.6	4.3 ± 0.6	3.4 ± 0.5	2.7 ± 0.2
Alogliptin	5.2 ± 0.7*	12.6 ± 1.0	8.5 ± 1.5*	4.9 ± 0.5*	4.7 ± 0.9*

Soluble VCAM-1(ng/ml)

Control	628 ± 72	622 ± 47	588 ± 72	637 ± 59	609.4 ± 46
Alogliptin	605 ± 50	614 ± 62	600 ± 62	619 ± 79	657 ± 69

Insulin (μIU/ml)

Control	4.8 ± 0.8	21.8 ± 6.4	5.2 ± 1.1	3.2 ± 0.5	2.6 ± 0.3
Alogliptin	4.9 ± 1.3	20.3 ± 5.0	5.5 ± 0.9	3.0 ± 0.5	3.0 ± 0.4

Endothelial function

Brachial artery diameter

(mm)

Control	4.02 ± 0.31	4.06 ± 0.57	4.04 ± 0.30	4.0 ± 0.24	3.94 ± 0.25
Alogliptin	3.91 ± 0.35	4.00 ± 0.40	4.01 ± 0.38	3.99 ± 0.39	3.97 ± 0.31

%FMD

Control	11.8 ± 0.6	9.4 ± 0.7	7.7 ± 0.3	10.3 ± 0.5	12.3 ± 0.5
Alogliptin	11.2 ± 0.4	9.1 ± 0.3	9.2 ± 0.5	10.0 ± 0.3	11.2 ± 0.5

%NMD

Control	19.8 ± 5.8	-	-	-	-
Alogliptin	21.0 ± 6.8	-	-	-	-

Data are the mean ± SE. Total-C, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; FMD, flow-mediated dilation; NMD, nitroglycerin-mediated dilation; *p < 0.05, vs. control group after treatment for 1 week.

Figure 1

